Risk of neoplastic change in large gastric hyperplastic polyps and recurrence after endoscopic resection
- PMID: 32120411
- DOI: 10.1055/a-1117-3166
Risk of neoplastic change in large gastric hyperplastic polyps and recurrence after endoscopic resection
Abstract
Background: Gastric hyperplastic polyps (GHPs) have a risk of neoplastic transformation reaching 5 %. Current endoscopic resection techniques appear suboptimal with a high risk of local recurrence. This study assessed the outcomes of endoscopic resection for GHPs and identified risk factors for recurrence and neoplastic transformation.
Methods: This retrospective, multicenter, European study included adult patients with at least one GHP ≥ 10 mm who underwent endoscopic resection and at least one follow-up endoscopy. Patients with recurrent GHPs or hereditary gastric polyposis were excluded. All data were retrieved from the endoscopy, pathology, and hospitalization reports.
Results: From June 2007 to August 2018, 145 GHPs in 108 patients were included. Recurrence after endoscopic resection was 51.0 % (74 /145) in 55 patients. R0 resection or en bloc resection did not impact the risk of polyp recurrence. In multivariate analysis, cirrhosis was the only risk factor for recurrence (odds ratio [OR] 4.82, 95 % confidence interval [CI] 1.33 - 17.46; P = 0.02). Overall, 15 GHPs (10.4 %) showed neoplastic transformation, with size > 25 mm (OR 10.24, 95 %CI 2.71 - 38.69; P < 0.001) and presence of intestinal metaplasia (OR 5.93, 95 %CI 1.56 - 22.47; P = 0.01) being associated with an increased risk of neoplastic transformation in multivariate analysis.
Conclusions: Results confirmed the risk of recurrence and neoplastic transformation of large GHPs. The risk of neoplastic change was significantly increased for lesions > 25 mm, with a risk of high grade dysplasia appearing in polyps ≥ 50 mm. The risk of recurrence was high, particularly in cirrhosis patients, and long-term follow-up is recommended in such patients.
© Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
Dr. Pioche has provided training funded by Olympus, Norgine, and Cook. Dr. Vanbiervliet is a consultant for Boston Scientific Corp. and Cook Medical. Dr. Albéniz has participated in practical courses or talks with Olympus, Boston, Norgine, and Casen-Recordati, and has received a grant from “La Caixa/Caja Navarra” Foundation. Dr. Marín-Gabriel has provided training funded by Olympus Iberia, SimMedica, Norgine Iberia, Casen Recordati, and Cook, and has received research funding from Cook. Dr. Giovannini is a consultant for Cook Medical and Pentax Medical. All other authors declare no conflicts of interest.
Comment in
-
Large gastric hyperplastic polyps: to resect or not to resect, that is the question!Endoscopy. 2020 Jun;52(6):424-426. doi: 10.1055/a-1151-8628. Epub 2020 May 27. Endoscopy. 2020. PMID: 32460332 No abstract available.
-
Gastric hyperplastic polyps (hyperplasiogenic polyps): a constant debate!Endoscopy. 2021 Jan;53(1):100. doi: 10.1055/a-1217-0521. Epub 2020 Dec 17. Endoscopy. 2021. PMID: 33333576 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
